Grace Hyun J Kim1,2, Stephan S Weigt3, John A Belperio3, Matthew S Brown4, Yu Shi5, Joshua H Lai4, Jonathan G Goldin4. 1. David Geffen School of Medicine, Radiological Science, UCLA, 924 Westwood Blvd. Ste 650, Box 957319, Los Angeles, CA, 90095-7319, USA. gracekim@mednet.ucla.edu. 2. Fielding School of Public Health, Biostatistics, Computer Vision and Imaging Biomarkers, UCLA, 924 Westwood Blvd. Ste 650, Box 957319, Los Angeles, CA, 90095-7319, USA. gracekim@mednet.ucla.edu. 3. UCLA Med-Pul Critical Care, Los Angeles, USA. 4. David Geffen School of Medicine, Radiological Science, UCLA, 924 Westwood Blvd. Ste 650, Box 957319, Los Angeles, CA, 90095-7319, USA. 5. Fielding School of Public Health, Biostatistics, Computer Vision and Imaging Biomarkers, UCLA, 924 Westwood Blvd. Ste 650, Box 957319, Los Angeles, CA, 90095-7319, USA.
Abstract
OBJECTIVE: High-resolution computed tomography (HRCT) plays an indispensable role in the diagnosis of idiopathic pulmonary fibrosis (IPF). Due to unpredictability in progression and the short median survival of 2-5 years, it is critical to delineate the patients with rapid progression. The aim is to evaluate the predictability of IPF progression using the early quantitative changes. METHODS: Automated texture-based quantitative lung fibrosis (QLF) was calculated from the anonymized HRCT. Two datasets were collected retrospectively: (1) a pilot study of 35 subjects with three sequential scans (baseline and 6 and 12 months) to obtain a threshold, where visual assessments were stable at 6 months but worsened at 12 months; (2) 157 independent subjects to test the threshold. Landmark Cox regressions were used to compare the progression-free survival (PFS) defined by pulmonary function using the threshold from the early changes in QLF. C-indexes were reported as estimations of the concordance of prediction. RESULTS: A threshold of 4% QLF change at 6 months corresponded to the mean change that worsened on HRCT visually at 12 months from the pilot study. Using the threshold, significant differences were found in the independent dataset (hazard ratio (HZ) = 5.92, p = 0.001 by Cox model, C-index = 0.71 at the most severe lobe; and HZ = 3.22, p = 0.012, C-index = 0.68 in the whole lung). Median PFS was 11.9 months for subjects with ≥ 4% changes, whereas median PFS was greater than 18 months for subjects with < 4% changes at the most severe lobe. CONCLUSION: Early structural changes on HRCT using a quantitative score can predict progression in lung function. KEY POINTS: • Changes on HRCT using quantitative texture-based scores can play a pivotal role for providing information and an aid tool for timely management decision for patients with IPF. • Quantitative changes on HRCT of 4% or more, which matched 6-month prior changes with visual assessment of worsening, can play a pivotal role for providing prediction of clinical progression by 3-5 folds higher in the next incidence, compared with those of subjects with less than 4% changes. • Early structural changes of 4% or more in a paired HRCT scans derived by quantitative scores can predict the progression in lung function in 1-2 years in subjects with IPF, which is critical information for timely management decision for subjects with IPF where the median survival is 2 to 5 years.
OBJECTIVE: High-resolution computed tomography (HRCT) plays an indispensable role in the diagnosis of idiopathic pulmonary fibrosis (IPF). Due to unpredictability in progression and the short median survival of 2-5 years, it is critical to delineate the patients with rapid progression. The aim is to evaluate the predictability of IPF progression using the early quantitative changes. METHODS: Automated texture-based quantitative lung fibrosis (QLF) was calculated from the anonymized HRCT. Two datasets were collected retrospectively: (1) a pilot study of 35 subjects with three sequential scans (baseline and 6 and 12 months) to obtain a threshold, where visual assessments were stable at 6 months but worsened at 12 months; (2) 157 independent subjects to test the threshold. Landmark Cox regressions were used to compare the progression-free survival (PFS) defined by pulmonary function using the threshold from the early changes in QLF. C-indexes were reported as estimations of the concordance of prediction. RESULTS: A threshold of 4% QLF change at 6 months corresponded to the mean change that worsened on HRCT visually at 12 months from the pilot study. Using the threshold, significant differences were found in the independent dataset (hazard ratio (HZ) = 5.92, p = 0.001 by Cox model, C-index = 0.71 at the most severe lobe; and HZ = 3.22, p = 0.012, C-index = 0.68 in the whole lung). Median PFS was 11.9 months for subjects with ≥ 4% changes, whereas median PFS was greater than 18 months for subjects with < 4% changes at the most severe lobe. CONCLUSION: Early structural changes on HRCT using a quantitative score can predict progression in lung function. KEY POINTS: • Changes on HRCT using quantitative texture-based scores can play a pivotal role for providing information and an aid tool for timely management decision for patients with IPF. • Quantitative changes on HRCT of 4% or more, which matched 6-month prior changes with visual assessment of worsening, can play a pivotal role for providing prediction of clinical progression by 3-5 folds higher in the next incidence, compared with those of subjects with less than 4% changes. • Early structural changes of 4% or more in a paired HRCT scans derived by quantitative scores can predict the progression in lung function in 1-2 years in subjects with IPF, which is critical information for timely management decision for subjects with IPF where the median survival is 2 to 5 years.
Authors: Vincent Cottin; Nikhil A Hirani; David L Hotchkin; Anoop M Nambiar; Takashi Ogura; María Otaola; Dirk Skowasch; Jong Sun Park; Hataya K Poonyagariyagorn; Wim Wuyts; Athol U Wells Journal: Eur Respir Rev Date: 2018-12-21
Authors: Roland M du Bois; Derek Weycker; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Alex Kartashov; Lisa Lancaster; Paul W Noble; Ganesh Raghu; Steven A Sahn; Javier Szwarcberg; Michiel Thomeer; Dominique Valeyre; Talmadge E King Journal: Am J Respir Crit Care Med Date: 2011-08-15 Impact factor: 21.405
Authors: Xiaoping Wu; Grace H Kim; Margaret L Salisbury; David Barber; Brian J Bartholmai; Kevin K Brown; Craig S Conoscenti; Jan De Backer; Kevin R Flaherty; James F Gruden; Eric A Hoffman; Stephen M Humphries; Joseph Jacob; Toby M Maher; Ganesh Raghu; Luca Richeldi; Brian D Ross; Rozsa Schlenker-Herceg; Nicola Sverzellati; Athol U Wells; Fernando J Martinez; David A Lynch; Jonathan Goldin; Simon L F Walsh Journal: Am J Respir Crit Care Med Date: 2019-01-01 Impact factor: 21.405
Authors: H G Kim; D P Tashkin; P J Clements; G Li; M S Brown; R Elashoff; D W Gjertson; F Abtin; D A Lynch; D C Strollo; J G Goldin Journal: Clin Exp Rheumatol Date: 2010-11-03 Impact factor: 4.473
Authors: Ganesh Raghu; Mary Beth Scholand; João de Andrade; Lisa Lancaster; Yolanda Mageto; Jonathan Goldin; Kevin K Brown; Kevin R Flaherty; Mark Wencel; Jack Wanger; Thomas Neff; Frank Valone; John Stauffer; Seth Porter Journal: Eur Respir J Date: 2016-03-10 Impact factor: 16.671
Authors: K R Flaherty; E L Thwaite; E A Kazerooni; B H Gross; G B Toews; T V Colby; W D Travis; J A Mumford; S Murray; A Flint; J P Lynch; F J Martinez Journal: Thorax Date: 2003-02 Impact factor: 9.139
Authors: Brett Ley; Christopher J Ryerson; Eric Vittinghoff; Jay H Ryu; Sara Tomassetti; Joyce S Lee; Venerino Poletti; Matteo Buccioli; Brett M Elicker; Kirk D Jones; Talmadge E King; Harold R Collard Journal: Ann Intern Med Date: 2012-05-15 Impact factor: 25.391
Authors: Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble Journal: N Engl J Med Date: 2014-05-18 Impact factor: 91.245
Authors: Luca Richeldi; Roland M du Bois; Ganesh Raghu; Arata Azuma; Kevin K Brown; Ulrich Costabel; Vincent Cottin; Kevin R Flaherty; David M Hansell; Yoshikazu Inoue; Dong Soon Kim; Martin Kolb; Andrew G Nicholson; Paul W Noble; Moisés Selman; Hiroyuki Taniguchi; Michèle Brun; Florence Le Maulf; Mannaïg Girard; Susanne Stowasser; Rozsa Schlenker-Herceg; Bernd Disse; Harold R Collard Journal: N Engl J Med Date: 2014-05-18 Impact factor: 91.245
Authors: Steven D Nathan; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Roland M du Bois; Elizabeth A Fagan; Robert S Fishman; Ian Glaspole; Marilyn K Glassberg; Kenneth F Glasscock; Talmadge E King; Lisa Lancaster; David J Lederer; Zhengning Lin; Carlos A Pereira; Jeffrey J Swigris; Dominique Valeyre; Paul W Noble; Athol U Wells Journal: Thorax Date: 2016-03-11 Impact factor: 9.139
Authors: Dmytro Onishchenko; Robert J Marlowe; Che G Ngufor; Louis J Faust; Andrew H Limper; Gary M Hunninghake; Fernando J Martinez; Ishanu Chattopadhyay Journal: Nat Med Date: 2022-09-29 Impact factor: 87.241
Authors: Lisa Lancaster; Jonathan Goldin; Matthias Trampisch; Grace Hyun Kim; Jonathan Ilowite; Lawrence Homik; David L Hotchkin; Mitchell Kaye; Christopher J Ryerson; Nesrin Mogulkoc; Craig S Conoscenti Journal: Open Respir Med J Date: 2020-09-22